{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:23:04Z","timestamp":1747207384619,"version":"3.40.5"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Direct locoregional treatments were recently proposed for the local control\nof cervical and distant metastasis of thyroid cancer, but data on their use as part of a multimodality\napproach for primary thyroid tumors are poor. In this feasibility study, laser ablation (LTA)\nwas successfully used for the initial debulking of unresectable radioiodine-refractory thyroid cancer\nin sequential therapy with Tyrosine-Kinase Inhibitors (TKI).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Presentation:<\/jats:title>\n<jats:p>A 69-year-old woman underwent partial resection of papillary thyroid cancer\nwith extensive tracheal infiltration. Post-treatment whole-body scan (131I, 8140 MBq) showed the\nabsence of cervical thyroid uptake. The patient experienced a rapid increase in her cervical mass associated\nwith dysphonia, dyspnea, and dysphagia. Due to a concomitant severe hypertensive state\nand cardiac failure, the patient was treated with LTA after a multidisciplinary consultation. After local\nanesthesia, two 300 nm optic fibers were inserted into the lesion through 21G spinal needles.\nTwo illuminations with 4-watt output power and 3600 Joules energy delivery were performed with\na diode-laser source. LTA resulted in rapid cancer debulking, and mass volume decreased from\n23.9 to 7.5 mL resulting in significant improvement of pressure symptoms. Three months later, the\npatient was started on lenvatinib due to the initial regrowth of the tumor mass. The cervical tumor\nburden was controlled by TKI for 20 months when a rapid disease progression occurred, and the patient\ndied.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Discussion:<\/jats:title>\n<jats:p>Locally advanced, unresectable, and radioiodine-refractory thyroid tumors can be managed\nwith a novel multimodality approach. The initial debulking with LTA of the locally aggressive\ndisease results in rapid control of the tumor burden threatening patients\u2019 life and is effectively\nfollowed by long-term control with TKI treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Based on this experience, sequential multimodality treatment with an initial locally directed\nlaser ablation procedure followed by TKI therapy may be considered as a salvage option in\npatients with unresectable and rapidly progressive RR thyroid tumors.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871530321666210830093522","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T06:14:30Z","timestamp":1630476870000},"page":"357-362","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined Treatment with Laser Ablation and Tyrosine-Kinase Inhibitor\nas A Novel Multimodality Approach to Locally Advanced Thyroid Cancer:\nA Case Report"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2856-3764","authenticated-orcid":true,"given":"Agnese","family":"Persichetti","sequence":"first","affiliation":[{"name":"Department of Endocrinology &amp; Metabolism, Regina Apostolorum Hospital, Rome, Italy | Service of Pharmacovigilance, Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Monti","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Sant\u2019 Andrea Hospital, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Coccaro","sequence":"additional","affiliation":[{"name":"Civil Disability, National Social Welfare Institution, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Presciuttini","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Sant\u2019 Andrea Hospital, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Deiana","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Sant\u2019 Andrea Hospital, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Bizzarri","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Regina Apostolorum Hospital, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Regina Apostolorum Hospital, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-0528","authenticated-orcid":true,"given":"Vincenzo","family":"Triggiani","sequence":"additional","affiliation":[{"name":"Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases-Interdisciplinary Department of Medicine, University of Bari \u201cA. Moro\u201d, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4790-2733","authenticated-orcid":true,"given":"Enrico","family":"Papini","sequence":"additional","affiliation":[{"name":"Department of Endocrinology &amp; Metabolism, Regina Apostolorum Hospital, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinaldo","family":"Guglielmi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology &amp; Metabolism, Regina Apostolorum Hospital, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e4127","DOI":"10.7759\/cureus.4127","volume":"11","author":"Olson E.","year":"2019","unstructured":"Olson E.; Wintheiser G.; Wolfe K.M.; Droessler J.; Silberstein P.T.; Epidemiology of thyroid cancer: a review of the national cancer database, 2000-2013. Cureus 2019,11(2),e4127","journal-title":"Cureus"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1634\/theoncologist.2014-0313","volume":"20","author":"Gruber J.J.","year":"2015","unstructured":"Gruber J.J.; Colevas A.D.; Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 2015,20(2),113-126","journal-title":"Oncologist"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"572958","DOI":"10.3389\/fonc.2020.572958","volume":"19","author":"Carrillo J.F.","year":"2021","unstructured":"Carrillo J.F.; Flores J.M.; Espinoza G.; V\u00e1zquez-Romo R.; Ram\u00edrez-Ortega M.C.; Carrillo L.C.; Cort\u00e9s-Garc\u00eda B.Y.; Ochoa-Carrillo F.J.; O\u00f1ate-Oca\u00f1a L.F.; Treatment of unresectable differentiated thyroid carcinoma with upfront external radiotherapy and Salvage Surgery: A STROBE-Compliant Retrospective Cohort Study. Front Oncol 2021,19,572958","journal-title":"Front Oncol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/thy.2018.0509","volume":"29","author":"Ibrahimpasic T.","year":"2019","unstructured":"Ibrahimpasic T.; Ghossein R.; Shah J.P.; Ganly I.; Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid 2019,29(3),311-321","journal-title":"Thyroid"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1089\/thy.2020.0038","volume":"30","author":"Roth E.M.","year":"2020","unstructured":"Roth E.M.; Lubitz C.C.; Swan J.S.; James B.C.; Patient-reported quality-of-life outcome measures in the thyroid cancer population. Thyroid 2020,30(10),1414-1431","journal-title":"Thyroid"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.6004\/jnccn.2018.0089","volume":"16","author":"Haddad R.I.","year":"2018","unstructured":"Haddad R.I.; Nasr C.; Bischoff L.; Busaidy N.L.; Byrd D.; Callender G.; Dickson P.; Duh Q.Y.; Ehya H.; Goldner W.; Haymart M.; Hoh C.; Hunt J.P.; Iagaru A.; Kandeel F.; Kopp P.; Lamonica D.M.; McIver B.; Raeburn C.D.; Ridge J.A.; Ringel M.D.; Scheri R.P.; Shah J.P.; Sippel R.; Smallridge R.C.; Sturgeon C.; Wang T.N.; Wirth L.J.; Wong R.J.; Johnson-Chilla A.; Hoffmann K.G.; Gurski L.A.; NCCN guidelines insights: thyroid carcinoma, Version 2.2018. J Natl Compr Canc Netw 2018,16(12),1429-1440","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"Brose M.S.","year":"2014","unstructured":"Brose M.S.; Nutting C.M.; Jarzab B.; Elisei R.; Siena S.; Bastholt L.; de la Fouchardiere C.; Pacini F.; Paschke R.; Shong Y.K.; Sherman S.I.; Smit J.W.; Chung J.; Kappeler C.; Pe\u00f1a C.; Moln\u00e1r I.; Schlumberger M.J.; Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet 2014,384(9940),319-328","journal-title":"Lancet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1507\/endocrj.EJ16-0064","volume":"63","author":"Ito Y.","year":"2016","unstructured":"Ito Y.; Suzuki S.; Ito K.; Imai T.; Okamoto T.; Kitano H.; Sugitani I.; Sugino K.; Tsutsui H.; Hara H.; Yoshida A.; Shimizu K.; Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma. Endocr J 2016,63(7),597-602","journal-title":"Endocr J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"Schlumberger M.","year":"2015","unstructured":"Schlumberger M.; Tahara M.; Wirth L.J.; Robinson B.; Brose M.S.; Elisei R.; Habra M.A.; Newbold K.; Shah M.H.; Hoff A.O.; Gianoukakis A.G.; Kiyota N.; Taylor M.H.; Kim S.B.; Krzyzanowska M.K.; Dutcus C.E.; de las Heras B.; Zhu J.; Sherman S.I.; Lenvatinib Versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015,372(7),621-630","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/thy.2017.0205","volume":"28","author":"Berdelou A.","year":"2018","unstructured":"Berdelou A.; Borget I.; Godbert Y.; Nguyen T.; Garcia M.E.; Chougnet C.N.; Ferru A.; Buffet C.; Chabre O.; Huillard O.; Leboulleux S.; Schlumberger M.; Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 2018,28(1),72-78","journal-title":"Thyroid"},{"key":"ref=11","first-page":"1643","volume":"38","author":"Nervo A.","year":"2018","unstructured":"Nervo A.; Gallo M.; Sam\u00e0 M.T.; Felicetti F.; Alfano M.; Migliore E.; Marchisio F.; Berardelli R.; Arvat E.; Piovesan A.; Lenvatinib in advanced radioiodine-refractory thyroid cancer: A snapshot of real-life clinical practice. Anticancer Res 2018,38(3),1643-1649","journal-title":"Anticancer Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","volume":"118","author":"Locati L.D.","year":"2019","unstructured":"Locati L.D.; Piovesan A.; Durante C.; Bregni M.; Castagna M.G.; Zovato S.; Giusti M.; Ibrahim T.; Puxeddu E.; Fedele G.; Pellegriti G.; Rinaldi G.; Giuffrida D.; Verderame F.; Bertolini F.; Bergamini C.; Nervo A.; Grani G.; Rizzati S.; Morelli S.; Puliafito I.; Elisei R.; Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer 2019,118,35-40","journal-title":"Eur J Cancer"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/EJE-19-0763","volume":"182","author":"Aydemirli M.D.","year":"2020","unstructured":"Aydemirli M.D.; Kapiteijn E.; Ferrier K.R.M.; Ottevanger P.B.; Links T.P.; van der Horst-Schrivers A.N.A.; Broekman K.E.; Groenwold R.H.H.; Zwaveling J.; Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. Eur J Endocrinol 2020,182(2),131-138","journal-title":"Eur J Endocrinol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"Haugen B.R.","year":"2016","unstructured":"Haugen B.R.; Alexander E.K.; Bible K.C.; Doherty G.M.; Mandel S.J.; Nikiforov Y.E.; Pacini F.; Randolph G.W.; Sawka A.M.; Schlumberger M.; Schuff K.G.; Sherman S.I.; Sosa J.A.; Steward D.L.; Tuttle R.M.; Wartofsky L.; American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016,26(1),1-133","journal-title":"Thyroid"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/hed.24357","volume":"38","author":"Kiess A.P.","year":"2016","unstructured":"Kiess A.P.; Agrawal N.; Brierley J.D.; Duvvuri U.; Ferris R.L.; Genden E.; Wong R.J.; Tuttle R.M.; Lee N.Y.; Randolph G.W.; External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. Head Neck 2016,38(4),493-498","journal-title":"Head Neck"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1089\/thy.2016.0650","volume":"27","author":"Yang Z.","year":"2017","unstructured":"Yang Z.; Flores J.; Katz S.; Nathan C.A.; Mehta V.; Comparison of survival outcomes following postsurgical radioactive iodine versus external beam radiation in stage IV differentiated thyroid carcinoma. Thyroid 2017,27(7),944-952","journal-title":"Thyroid"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1201\/b10945-14","author":"Papini E.","year":"2011","unstructured":"Papini E.; Bianchini A.; Guglielmi R.; Pacella C.M.; Misischi I.; Bizzarri G.;  Thyroid Cancer 2011,213-230","journal-title":"Thyroid Cancer"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00270-016-1313-6","volume":"39","author":"Mauri G.","year":"2016","unstructured":"Mauri G.; Cova L.; Ierace T.; Baroli A.; Di Mauro E.; Pacella C.M.; Goldberg S.N.; Solbiati L.; Treatment of metastatic lymph nodes in the neck from papillary thyroid carcinoma with percutaneous laser ablation. Cardiovasc Intervent Radiol 2016,39(7),1023-1030","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1245\/s10434-011-1619-1","volume":"18","author":"Park K.W.","year":"2011","unstructured":"Park K.W.; Shin J.H.; Han B.K.; Ko E.Y.; Chung J.H.; Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. Ann Surg Oncol 2011,18(9),2564-2568","journal-title":"Ann Surg Oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"W331-6","DOI":"10.2214\/AJR.10.5345","volume":"197","author":"Baek J.H.","year":"2011","unstructured":"Baek J.H.; Kim Y.S.; Sung J.Y.; Choi H.; Lee J.H.; Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol 2011,197(2),W331-6","journal-title":"AJR Am J Roentgenol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"E92","DOI":"10.1210\/jc.2012-2991","volume":"98","author":"Papini E.","year":"2013","unstructured":"Papini E.; Bizzarri G.; Bianchini A.; Valle D.; Misischi I.; Guglielmi R.; Salvatori M.; Solbiati L.; Crescenzi A.; Pacella C.M.; Gharib H.; Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer. J Clin Endocrinol Metab 2013,98(1),E92-E97","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/02656736.2018.1508759","volume":"35","author":"Persichetti A.","year":"2018","unstructured":"Persichetti A.; Bizzarri G.; Guglielmi R.; Barnabei A.; Bianchini A.; Coccaro C.; Appetecchia M.; Papini E.; Ultrasound-guided laser ablation for local control of neck recurrences of medullary thyroid cancer. A feasibility study. Int J Hyperthermia 2018,35(1),480-492","journal-title":"Int J Hyperthermia"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s12020-020-02314-4","volume":"70","author":"Pacella C.M.","year":"2020","unstructured":"Pacella C.M.; Di Stasio E.; Guglielmi R.; Baroli A.; Pedrazzini L.; Misischi I.; Persichetti A.; Papini E.; Role of laser ablation in multimodal treatment of radioiodine- refractory bone metastases of thyroid cancer: A retrospective study. Endocrine 2020,70(2),338-347","journal-title":"Endocrine"},{"year":"2010","author":"Rogers S.N.","key":"ref=24","unstructured":"Rogers S.N.; Lowe D.; The University of Washington quality of life (UW- QoL) scale for \"Handbook of Disease Burdens and Quality of Life Measures\". Available from:  2010"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3348\/kjr.2012.13.2.117","volume":"13","author":"Na D.G.","year":"2012","unstructured":"Na D.G.; Lee J.H.; Jung S.L.; Kim J.H.; Sung J.Y.; Shin J.H.; Kim E.K.; Lee J.H.; Kim D.W.; Park J.S.; Kim K.S.; Baek S.M.; Lee Y.; Chong S.; Sim J.S.; Huh J.Y.; Bae J.I.; Kim K.T.; Han S.Y.; Bae M.Y.; Kim Y.S.; Baek J.H.; Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol 2012,13(2),117-125","journal-title":"Korean J Radiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000508484","volume":"9","author":"Papini E.","year":"2020","unstructured":"Papini E.; Monpeyssen H.; Frasoldati A.; Heged\u00fcs L.; European thyroid association clinical practice guideline for the use of image-guided ablation in benign thyroid nodules. Eur Thyroid J 2020,9(4),172-185","journal-title":"Eur Thyroid J"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1089\/thy.2019.0707","volume":"30","author":"Choi Y.","year":"2020","unstructured":"Choi Y.; Jung S.L.; Efficacy and safety of thermal ablation techniques for the treatment of primary papillary thyroid microcarcinoma: a systematic review and meta-analysis. Thyroid 2020,30(5),720-731","journal-title":"Thyroid"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1080\/02656736.2019.1700559","volume":"36","author":"Tong M.","year":"2019","unstructured":"Tong M.; Li S.; Li Y.; Li Y.; Feng Y.; Che Y.; Efficacy and safety of radiofrequency, microwave and laser ablation for treating papillary thyroid microcarcinoma: A systematic review and meta-analysis. Int J Hyperthermia 2019,36(1),1278-1286","journal-title":"Int J Hyperthermia"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000516469","volume":"10","author":"Mauri G.","year":"2021","unstructured":"Mauri G.; Heged\u00fcs L.; Bandula S.; Cazzato R.L.; Czarniecka A.; Dudeck O.; Fugazzola L.; Netea-Maier R.; Russ G.; Wallin G.; Papini E.; European thyroid association and cardiovascular and interventional radiological society of europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J 2021,10(3),185-197","journal-title":"Eur Thyroid J"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00270-021-02870-w","volume":"27","author":"Mauri G.","year":"2021","unstructured":"Mauri G.; Heged\u00fcs L.; Cazzato R.L.; Papini E.; Minimally invasive treatment procedures have come of age for thyroid malignancy: the 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Cardiovasc Intervent Radiol 2021,27(9),1481-1484","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871530321666210830093522","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/195922\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871530321666210830093522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T02:06:13Z","timestamp":1658282773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/195922\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530321666210830093522","relation":{},"ISSN":["1871-5303"],"issn-type":[{"type":"print","value":"1871-5303"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}